{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:04:16Z","timestamp":1760061856198,"version":"3.40.4"},"reference-count":60,"publisher":"Informa UK Limited","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.4155\/bio.13.147","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T11:25:30Z","timestamp":1376393130000},"page":"2053-2069","source":"Crossref","is-referenced-by-count":7,"title":["Application of Population Pharmacokinetics for Preclinical Safety and Efficacy Studies"],"prefix":"10.1080","volume":"5","author":[{"given":"Stefano","family":"Porzio","sequence":"first","affiliation":[{"name":"Professional Advertising & Services \u2013 Preclinical Development, Via Monte Generoso 4, PO Box 111, 22077 - Olgiate Comasco, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"e_1_3_3_3_1_1","first-page":"127","volume-title":"Pharmacokinetics in Drug Development. Volume 2: Regulatory and Development Paradigms","author":"Natarajan C","year":"2004","unstructured":"Natarajan C , RohatagiS. Role of preclinical PK in drug development. In:Pharmacokinetics in Drug Development. Volume 2: Regulatory and Development Paradigms. AAPS Press, VA, USA, 127\u2013161 (2004)."},{"key":"e_1_3_3_3_2_1","first-page":"235","volume-title":"Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis","author":"Muir KT","year":"2004","unstructured":"Muir KT , GomeniR. Non-compartmental analysis. In: Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis. AAPS Press, VA, USA, 235\u2013265 (2004)."},{"key":"e_1_3_3_3_3_1","first-page":"161","volume-title":"Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application. Fourth Edition","author":"Gabriellsson J","year":"2006","unstructured":"Gabriellsson J , WeinerD. Pharmacokinetic concepts \u2013 non compartmental analysis. In:Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application. Fourth Edition. Swedish Pharmaceutical Press, Stockholm, Sweden, 161\u2013180 (2006)."},{"key":"e_1_3_3_3_4_1","first-page":"205","article-title":"Kinetics of distributions of substances administered to the body","volume":"57","author":"Teorell T","year":"1937","unstructured":"Teorell T . Kinetics of distributions of substances administered to the body. Archives Internat. Pharmacodyn. Ther. 57, 205\u2013240 (1937).","journal-title":"Archives Internat. Pharmacodyn. Ther"},{"volume-title":"Population Pharmacokinetics. Guidance for Industry \u2013 US Department of Health and Human Services. Food and Drug Administration","key":"e_1_3_3_3_5_1","unstructured":"US FDA Center for Drug Evaluation and Research (CDER). Population Pharmacokinetics. Guidance for Industry \u2013 US Department of Health and Human Services. Food and Drug Administration. February 1999."},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-27199-6_3"},{"key":"e_1_3_3_3_7_1","first-page":"389","volume-title":"Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application. Fourth Edition","author":"Gabriellsson J","year":"2006","unstructured":"Gabriellsson J , WeinerD. Modeling Strategies. In:Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application. Fourth Edition. Swedish Pharmaceutical Press, Stockholm, Sweden, 389\u2013463 (2006)."},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059398"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1063\/1.3295638"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9942-y"},{"key":"e_1_3_3_3_11_1","first-page":"341","volume-title":"Pharmacokinetic\u2013Pharmacodynamic Modeling and Simulation","author":"Bonate PL","year":"2006","unstructured":"Bonate PL . Appendix. In:Pharmacokinetic\u2013Pharmacodynamic Modeling and Simulation. Springer Science+Business Media Inc., NY, USA, 341\u2013364 (2006)."},{"key":"e_1_3_3_3_12_1","first-page":"501","volume-title":"Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis","author":"Mould RD","year":"2004","unstructured":"Mould RD . Population pharmacokinetics: applications in industry. In:Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis. AAPS Press, VA, USA, 501\u2013529 (2004)."},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-27199-6_7"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2003.10.006"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/507294"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-5383-1"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0209-y"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10266"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.01.019"},{"key":"e_1_3_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2005.05.010"},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034488"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2011.04.008"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.009746"},{"key":"e_1_3_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1542-3"},{"key":"e_1_3_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1683"},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1152"},{"issue":"3","key":"e_1_3_3_3_27_1","first-page":"602","article-title":"Drug disease interactions: role of inflammatory mediators in disease and variability in drug response","volume":"8","author":"Kulmatycki KM","year":"2005","unstructured":"Kulmatycki KM , JamaliF. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J. Pharm. Pharmaceut. Sci. 8(3), 602\u2013625 (2005).","journal-title":"J. Pharm. Pharmaceut. Sci"},{"key":"e_1_3_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.626"},{"key":"e_1_3_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0262-z"},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.313"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.138-143.2003"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05208-11"},{"key":"e_1_3_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-07"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.09.029"},{"issue":"4","key":"e_1_3_3_3_36_1","first-page":"1","article-title":"Evaluation of blood\u2013brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson\u2019s disease","volume":"9","author":"Ravenstijn PG","year":"2012","unstructured":"Ravenstijn PG , DrenthHJ, O\u2019NeillMJ, DanhofM, de Lange EC. Evaluation of blood\u2013brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson\u2019s disease. Fluids and Barriers of the CNS9(4), 1\u201314 (2012).","journal-title":"Fluids and Barriers of the CNS"},{"key":"e_1_3_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016117218760"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000070400"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)00801-9"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1037\/0735-7044.117.5.1076"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20200"},{"key":"e_1_3_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070370"},{"key":"e_1_3_3_3_43_1","first-page":"423","volume-title":"Pharmacokinetics in Drug Development (Volume 1: Clinical Study Design and Analysis)","author":"Mahmood I","year":"2004","unstructured":"Mahmood I . Interspecies pharmacokinetic scaling: principles, applications, and limitations. In:Pharmacokinetics in Drug Development (Volume 1: Clinical Study Design and Analysis). AAPS Press, Arlington, VA, USA, 423\u2013444 (2004)."},{"key":"e_1_3_3_3_44_1","first-page":"207","volume-title":"Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists","author":"Kwon Y","year":"2002","unstructured":"Kwon Y . Predicting pharmacokinetics in human. In:Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. Kluwer Academic Publishers, NY, USA 207\u2013228 (2002)."},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach RS","year":"1997","unstructured":"Obach RS , BaxterJG, ListonTEet al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283, 46\u201358 (1997).","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"e_1_3_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059667"},{"key":"e_1_3_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600751104"},{"key":"e_1_3_3_3_48_1","first-page":"193","volume-title":"Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application (4th Edition)","author":"Gabriellsson J","year":"2006","unstructured":"Gabriellsson J , WeinerD. Pharmacokinetic concepts \u2013 inter-species scaling. In:Pharmacokinetic & Pharmacodynamic Data Analysis: Concepts and Application (4th Edition). Swedish Pharmaceutical Press, Stockholm, Sweden, 193\u2013224 (2006)."},{"key":"e_1_3_3_3_49_1","unstructured":"Center for Drug Evaluation and Research (CDER). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Guidance for Industry \u2013 US Department of Health and Human Services. US FDA. July 2005."},{"key":"e_1_3_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1412-z"},{"key":"e_1_3_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2005.01.002"},{"key":"e_1_3_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623309332986"},{"key":"e_1_3_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191999"},{"key":"e_1_3_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00513.x"},{"key":"e_1_3_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3439"},{"key":"e_1_3_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.10.245"},{"key":"e_1_3_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2010.04.007"},{"key":"e_1_3_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874467211205020301"},{"key":"e_1_3_3_3_59_1","doi-asserted-by":"crossref","unstructured":"Rogers M LysterP OkitaR. NIH Support for the Emergence of Quantitative and Systems Pharmacology CPT: Pharmacometrics & Systems Pharmacology. 2 e37 (2013).","DOI":"10.1038\/psp.2013.1"},{"key":"e_1_3_3_4_2_1","unstructured":"Population PK\/PD modeling of a fully humanized monoclonal antibody in monkey to guide the first time in man studies. Rosen\u00f6n meeting on DMPK and PK\/PD from Lead to Product Rosen\u00f6n Stockholm Sweden September 20\u201322 2007. www.pharsight.com\/library\/Rosenon2007.pdf"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/bio.13.147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T13:50:44Z","timestamp":1746021044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/bio.13.147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":60,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.4155\/bio.13.147"],"URL":"https:\/\/doi.org\/10.4155\/bio.13.147","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"type":"print","value":"1757-6180"},{"type":"electronic","value":"1757-6199"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}